中国药物评价2016，Vol.33Issue(1)：47-50,4.
中日药品数据保护制度的比较研究
Comparative Study on Pharmaceutical Data Protection System of China and Japan
摘要
Abstract
After joining World Trade Organization( WTO) , the Chinese government carried out pharmaceutical data protection under the TRIPS agreement, but there are still some deficiencies in the pharmaceutical data protection system of China.The rapid progress in the pharmaceutical industry of Japan was tightly related to the implement of pharmaceutical industry related polices, the re-investigation policy of post-marketing drugs in Japan not only played an important role in stimulating the initiatives of drug research companies, but also effec-tively weakened the side effects of the data protection system.By comparative study on pharmaceutical data protection system of China and Japan, this paper aims to find out the shortcomings existing in the process of the pharmaceutical data protection in China and provide some feasible suggestion for the further improvement of Chinese pharmaceutical data protection system.关键词
药品数据保护/TRIPS协议/药品可及性Key words
Pharmaceutical data protection/TRIPS agreement/Drug accessibility分类
医药卫生引用本文复制引用
庞晓丛,康德,刘艾林,杜冠华..中日药品数据保护制度的比较研究[J].中国药物评价,2016,33(1):47-50,4.基金项目
十二五重大新药创制项目 （）
